Furthermore, EGFR-mutant NSCLC cells with high PD-L1 expression are resistant to gefitinib due to PD-L1 overexpression that can trigger EMT through activation of the TGF-β/Smad pathway [87]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.